Applying Molecular Modeling to the Design of Innovative, Non-Symmetrical CXCR4 Inhibitors with Potent Anticancer...

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Oncology

Background:

• CXC chemokine receptor type 4 (CXCR4) antagonists are actively researched for therapeutic applications, particularly in oncology.
• AMD3100 derivatives and molecular modeling have been key in discovering new CXCR4-targeting compounds.
• The continued relevance of molecular design in identifying novel drug candidates is under investigation.

Purpose of the Study:

• To construct and screen a large virtual library of tetraamines for potential CXCR4 inhibitory activity.
• To identify novel compounds with potential antitumor activity against diffuse large B-cell lymphoma (DLBCL).
• To evaluate the role of molecular design in the development of new CXCR4 inhibitor candidates.

Main Methods:

• Construction of a virtual library of 450,000 tetraamines using diverse spacers and diamines.
• Application of diversity selection for virtual screening of the tetraamine library.
• Molecular docking simulations against the CXCR4 crystal structure to rank candidate molecules.

Main Results:

• Identification of a non-symmetrical, synthetically feasible compound (A{17,18}) with promising in vitro activity against DLBCL.
• Discovery of potential pre-hit compounds (IC50~20 µM) among symmetrical tetraamine derivatives.
• Validation of molecular design strategies in the search for novel CXCR4 inhibitors.

Conclusions:

• Molecular modeling and virtual screening remain powerful tools for identifying novel CXCR4 inhibitors.
• Compound A{17,18} represents a promising lead for further development against DLBCL.
• The study underscores the ongoing importance of rational molecular design in drug discovery for CXCR4-related diseases.